Insulet Corporation Q3 FY2026 results
$152.48+2.14%
Insulet Corporation reported revenue of $842 million, up 19.2% from a year earlier, net income of $141 million and diluted earnings per share of $2.03 against $1.24 for the third quarter of fiscal 2026 (the three months to 30 Sep 2026).
From its quarterly report, filed 4 Nov 2026. Compiled and checked by AapWire.
Q3 FY2026 against Q3 FY2025
Three months to 30 Sep 2026, against the three months to 30 Sep 2025. Amounts in USD.
| Measure | Q3 FY2026 | Q3 FY2025 | Change |
|---|---|---|---|
| Revenue | $842.0M | $706.3M | +19.2% |
| Gross profit | $632.1M | $510.1M | +23.9% |
| Gross margin | 75.1% | 72.2% | +2.8 pts |
| Operating income | $189.8M | $117.7M | +61.3% |
| Operating margin | 22.5% | 16.7% | +5.9 pts |
| Net income | $141.1M | $87.60M | +61.1% |
| Diluted EPS | $2.03 | $1.24 | +63.7% |
| Operating cash flow | $123.5M | $125.7M | −1.8% |
| Capital expenditure | $57.10M | $25.60M | +123% |
| Free cash flow | $66.40M | $100.1M | −33.7% |
Operating KPIs for the quarter
| KPI | Q3 FY2026 | Change on a year |
|---|---|---|
| U.S. revenue | $570.4M | up 14.7% |
| International revenue | $266.2M | up 31.7% |
| Drug Delivery revenue | $5.5M | down 22.5% |
Earlier quarters
| Quarter | Period end | Revenue | Change on a year | Diluted EPS |
|---|---|---|---|---|
| Q3 FY2026 | 30 Sep 2026 | $842.0M | +19.2% | $2.03 |
| Q2 FY2026 | 30 Jun 2026 | $801.7M | +23.5% | $1.37 |
| Q1 FY2026 | 31 Mar 2026 | $761.7M | +33.9% | $1.30 |
| Q4 FY2025 | 31 Dec 2025 | $783.8M | +31.2% | $1.44 |
| Q3 FY2025 | 30 Sep 2025 | $706.3M | +29.9% | $1.24 |
| Q2 FY2025 | 30 Jun 2025 | $649.1M | +32.9% | $0.32 |
| Q1 FY2025 | 31 Mar 2025 | $569.0M | +28.8% | $0.50 |
| Q4 FY2024 | 31 Dec 2024 | $597.5M | +17.2% | $1.39 |
More on Insulet Corporation: financial statements · revenue · earnings per share
PODD's results, as they are filed.
Releases read within minutes, guidance against results, the quarter in its eight-quarter history, and an alert on each new report.